Revance Therapeutics Inc (NASDAQ:RVNC) has received a consensus rating of “Buy” from the fourteen ratings firms that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $49.71.
A number of equities analysts have commented on RVNC shares. Cantor Fitzgerald reissued a “buy” rating and issued a $50.00 price objective on shares of Revance Therapeutics in a research note on Friday, September 14th. JMP Securities lowered Revance Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, September 17th. Zacks Investment Research lowered Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, October 4th. ValuEngine raised Revance Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, BidaskClub lowered Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, July 20th.
Institutional investors and hedge funds have recently modified their holdings of the company. Cubist Systematic Strategies LLC acquired a new position in shares of Revance Therapeutics during the first quarter valued at $189,000. Xact Kapitalforvaltning AB acquired a new position in shares of Revance Therapeutics during the second quarter valued at $209,000. Verition Fund Management LLC acquired a new position in shares of Revance Therapeutics during the first quarter valued at $233,000. Levin Capital Strategies L.P. acquired a new position in shares of Revance Therapeutics during the first quarter valued at $277,000. Finally, Metropolitan Life Insurance Co. NY lifted its stake in shares of Revance Therapeutics by 25.8% during the second quarter. Metropolitan Life Insurance Co. NY now owns 10,875 shares of the biopharmaceutical company’s stock valued at $299,000 after acquiring an additional 2,232 shares during the period. 94.35% of the stock is currently owned by institutional investors and hedge funds.
Revance Therapeutics stock opened at $23.92 on Friday. The firm has a market capitalization of $917.91 million, a price-to-earnings ratio of -5.97 and a beta of 1.30. Revance Therapeutics has a 52 week low of $22.25 and a 52 week high of $37.45.
Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.02). The business had revenue of $0.69 million during the quarter, compared to analyst estimates of $0.93 million. Revance Therapeutics had a negative return on equity of 63.30% and a negative net margin of 13,690.62%. Sell-side analysts expect that Revance Therapeutics will post -3.9 EPS for the current year.
About Revance Therapeutics
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.
Further Reading: What are the reasons investors use put options?
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.